Abstract: The invention relates to methods of producing eukaryotic cell libraries encoding a repertoire of binding molecules (“binders”), wherein the methods use a site-specific nuclease for targeted cleavage of cellular DNA to enhance site-specific integration of binder genes through endogenous cellular repair mechanisms. Populations of eukaryotic cells are produced in which a repertoire of genes encoding binders are integrated into a desired locus in cellular DNA (e.g., a genomic locus) allowing expression of the encoded binding molecule, thereby creating a population of cells expressing different binders.
Type:
Grant
Filed:
February 11, 2020
Date of Patent:
March 12, 2024
Assignee:
Iontas Limited
Inventors:
John McCafferty, Michael Dyson, Kothai Parthiban
Abstract: A synthetic lentiviral vector construct comprises a genomic RNA packaging enhancer (GRPE) element and lentiviral nucleic acid sequences sufficient for reverse transcription and packaging in a host cell.
Abstract: The invention relates to methods of producing eukaryotic cell libraries encoding a repertoire of binding molecules (“binders”), wherein the methods use a site-specific nuclease for targeted cleavage of cellular DNA to enhance site-specific integration of binder genes through endogenous cellular repair mechanisms. Populations of eukaryotic cells are produced in which a repertoire of genes encoding binders are integrated into a desired locus in cellular DNA (e.g., a genomic locus) allowing expression of the encoded binding molecule, thereby creating a population of cells expressing different binders.
Type:
Grant
Filed:
February 11, 2020
Date of Patent:
February 27, 2024
Assignee:
Iontas Limited
Inventors:
John McCafferty, Michael Dyson, Kothai Parthiban
Abstract: The invention relates to the liver-specific delivery and/or expression of an enzyme which has a deoxyribonuclease (DNase) activity for enhanced clearance of cell free DNA (cfDNA) accumulated in hepatic porto-sinusoidal circulation and the use of such liver-specific delivery and/or expression for treatment of various diseases and conditions, including cancer and neurodegeneration.
Type:
Grant
Filed:
January 15, 2019
Date of Patent:
February 20, 2024
Assignee:
CLS THERAPEUTICS LIMITED
Inventors:
Dmitry Dmitrievich Genkin, Georgy Viktorovich Tets, Viktor Veniaminovich Tets
Abstract: The present disclosure relates to recombinant viral vectors, to pharmaceutical compositions comprising such recombinant vectors, and to methods for prevention and treatment of osteoarthritis in mammals. In particular, this disclosure provides adeno-associated virus (AAV) vectors capable of expressing, in a host, osteoprotective/chondroprotective bioactive proteins, including hyaluronan synthase 2 (HAS2) and lubricin (PRG4). Methods of production of these AAV are provided, as are methods of treatment of osteoarthritis in mammalian joints, by the long-term gene expression of osteoprotective/chondroprotective proteins, including HAS2 and PRG4, in both synovial and chondrocyte cells.
Type:
Grant
Filed:
July 29, 2019
Date of Patent:
February 20, 2024
Assignees:
GENZYME CORPORATION, BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
Inventors:
Monica Dias Figueiredo, Sirkka R M Kyostio-Moore, Patricia Berthelette
Abstract: The invention provides a method of differentiating human pluripotent stem cells to ectodermal cell by treating human pluripotent stem cells, which are dissociated single cells, and inducing differentiation to ectodermal cells under conditions where a ROCK(Rho-kinase) inhibitor is present in a culture medium in contact with the cells after dissociation of the human pluripotent stem cells.
Abstract: Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
Type:
Grant
Filed:
May 17, 2020
Date of Patent:
February 6, 2024
Assignee:
CELLECTIS
Inventors:
Roman Galetto, Agnes Gouble, Stephanie Grosse, Cecile Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
Abstract: The invention relates to adenoviral vectors, cells for use in generating adenoviral vectors, methods for generating adenoviral vectors, and therapeutic uses of adenoviral vectors in gene therapy, tumour therapy and as vaccines.
Type:
Grant
Filed:
April 6, 2017
Date of Patent:
January 9, 2024
Assignee:
Gene Bridges GMBH
Inventors:
Adrian Francis Stewart, Jun Fu, Anja Ehrhardt, Eric Ehrke-Schulz, Wenli Zhang
Abstract: A eukaryotic replicative pUC-free minicircle expression vector is provided. The eukaryotic replicative pUC-free minicircle expression vector includes a pUC-free eukaryotic region sequence encoding a transgene of interest and comprising 5? and 3? ends and a ii) pUC-free spacer region of less than 500 basepairs in length linking the 5? and 3? ends of the eukaryotic region sequences and comprising a bacterial R6K replication origin having at least 95% sequence identity to SEQ ID NO: 11 and SEQ ID NO: 12 and a RNA selectable marker, the RNA selectable marker being an RNA-IN regulating RNA-OUT functional variant having at least 95% sequence identity to SEQ ID NO: 20 or SEQ ID NO: 22.
Abstract: The present subject matter provides a method for delivering a gene editing composition across a plasma membrane of a cell. Related apparatus, system, techniques, compositions, and articles are also described.
Abstract: An isolated polynucleotide includes a nucleic acid sequence that includes a cDNA coding sequence of a clarin-1 gene and a 3?UTR nucleic acid that is derived from the 3?UTR of the clarin-1 gene. The 3?UTR nucleic acid can enhance expression of clarin-1 in a cell transfected with the polynucleotide compared to a cell transfected with a similar polynucleotide devoid of the 3?UTR nucleic acid.
Abstract: Mesenchymal stem cells which express TNF-? receptor Type I in an amount of at least 13 pg/106 cells. Such mesenchymal stem cells inhibit the proliferation of lymphocytes and may be employed, in particular, in the treatment of graft-versus-host disease.
Type:
Grant
Filed:
November 2, 2020
Date of Patent:
November 21, 2023
Assignee:
MESOBLAST INTERNATIONAL SÁRL
Inventors:
Alla Danilkovitch, Diane Carter, Alicia Mildred Tyrell, Simon Bubnic, Michelle Marcelino, Rodney Monroy
Abstract: A simple, highly flexible and scalable platform for making functional complex tissues with heterogeneity and irregularity is provided. The method includes combining undifferentiated cells, such as pluripotent or multipotent stem cells, with a biomaterial to make multiple undifferentiated or naïve subunits, exposing the undifferentiated or naïve subunits to different cell culture environments for induction of differentiation towards different lineages as required by that complex tissue, and combining the then functional subunits with or without the undifferentiated subunits. The differentiated subunits thus combined can be cultured under biological, chemical, and/or physical culture conditions suitable to fine-tune the structural and functional properties of the bioengineered complex tissue to form a bioengineered tissue graft that mimics the structural and functional characteristics of native complex tissue. The bioengineered tissue graft can then used to replace dysfunctional tissue.
Type:
Grant
Filed:
June 14, 2011
Date of Patent:
October 17, 2023
Assignee:
VERSITECH LIMITED
Inventors:
Barbara Pui Chan, Hiu Wa Cheng, Daniel Tsz Kit Chik, Kenneth Man Chee Cheung, Keith Dip Kei Luk
Abstract: The present disclosure provides codon optimized Factor VIII sequences, vectors, and host cells comprising codon optimized Factor VIII sequences, polypeptides encoded by codon optimized Factor VIII sequences, and methods of producing such polypeptides. The present disclosure also provides methods of treating bleeding disorders such as hemophilia comprising administering to the subject a codon optimized Factor VIII nucleic acid sequence or the polypeptide encoded thereby.
Abstract: The present invention concerns nucleic acids of interest for modulating the microbiome of a host, to vectors encoding the nucleic acids and to methods for in vivo modulating the microbiome of a subject by delivering the nucleic acids of interest.
Type:
Grant
Filed:
December 29, 2021
Date of Patent:
September 5, 2023
Assignee:
Eligo Bioscience
Inventors:
Jesus Fernandez Rodriguez, Xavier Duportet
Abstract: Aspects of the disclosure relate to compositions and methods useful for treating ocular ciliopathies, for example Leber congenital amaurosis (LCA). In some embodiments, the disclosure provides isolated nucleic acids comprising a transgene encoding a CEP290 protein fragment, and methods of treating ocular ciliopathies using the same.
Abstract: Compositions disclosed herein, and methods of use thereof included those for inhibiting or reducing the incidence of cytokine release syndrome or cytokine storm in a subject undergoing CAR T-cell therapy, wherein the subjects are administered compositions comprising apoptotic cells or apoptotic cell supernatants. In certain instances compositions and methods of use thereof disclosed herein do not reduce the efficacy of the CAR T-cell cancer therapy. Disclosed herein are also compositions and methods of use thereof for decreasing or inhibiting cytokine production in a subject experiencing cytokine release syndrome or cytokine storm comprising administration of a composition comprising apoptotic cells or an apoptotic cell supernatant.
Abstract: Aspects of the invention described herein concern the incorporation of a FOXP3 cDNA (e.g., full-length human codon-optimized cDNA) into a FOXP3 gene or a non-FOXP3 locus so as to provide constitutive or regulated FOXP3 expression in a primary human CD34+ cells or cells derived from edited CD34+ cells. In some embodiments, guide RNA sequences that are directed to FOXP3, AAVS1, or other candidate loci are used for CRISPR/Cas9-mediated gene regulation, and gene delivery cassettes for HDR based gene-modification are provided.
Type:
Grant
Filed:
April 25, 2019
Date of Patent:
August 1, 2023
Assignee:
SEATTLE CHILDREN'S HOSPITAL
Inventors:
David J. Rawlings, Iram F. Khan, Yuchi Chiang Honaker, Swati Singh, Karen Sommer, Andrew M. Scharenberg